Infinity Pharmaceuticals, Inc.

Report azionario OTCPK:INFI.Q

Capitalizzazione di mercato: US$90.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Infinity Pharmaceuticals Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Seth Tasker

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO7.7yrs
Proprietà del CEOn/a
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Articolo di analisi • Jun 03

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...

Recent updates

Articolo di analisi • Nov 10

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 08

Infinity Pharmaceuticals: Waiting For A Deal

Summary Today, we revisit small oncology concern Infinity Pharmaceuticals for the first time in 2022. The company's primary drug Eganelisib has shown encouraging results as part of combination therapies, but the company is waiting on a collaboration deal to move development forward. Is a key strategic partnership worth the wait? An investment analysis follows in the paragraphs below. A man might share his wealth, but never his authority. - Amit Kalantri We concluded our last piece on Infinity Pharmaceuticals (INFI) in November 2021 saying it probably merited a small 'watch item' holding, preferably with a covered call position. Today, we follow up and see how this small biotech firm is progressing. An analysis follows below. Seeking Alpha Company Overview: Infinity Pharmaceuticals is headquartered in Cambridge, MA and its main focus continues to be developing novel medicines to treat cancer. This small oncology firm has a market cap of approximately $135 million and the stock trades near $1.50 a share. Pipeline: The company's core focus continues to be to develop its primary drug candidate Eganelisib as part of combination therapies to treat a variety of oncology indications. Eganelisib is a first-in-class, oral, once-daily, immuno-oncology (I/O) development candidate selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). According to the company's website, Eganelisib works by: May Company Presentation Reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Company Website Since our last update around Infinity Pharmaceuticals, the company has disclosed some trial results. In December of last year, Infinity posted some updated data from its ongoing MARIO-3 study. This Phase 2 trial was designed to evaluate Eganelisib in combination with Roche's (RHHBY) atezolizumab (Tecentriq) and chemotherapy nab-paclitaxel (Abraxane) in frontline metastatic triple-negative breast cancer (TNBC). According to the lead scientist on the results showed 'Tumor reductions in 88.6% of evaluable patients were associated with a disease control rate of 81.4% in patients with PD-L1 negative tumors who are among the most challenging to treat'. The company should review updated PFS data from this study by the end of this year. Company Presentation Then a month ago, the company posted data from its two-year analysis of its phase 2 MARIO-275 study. This trial is evaluating Eganelisib in combination with Bristol-Myers' (BMY) Opdivo for the treatment of second line urothelial cancer. A key conclusion of the analysis was that 45% of patients in the Eganelisib combination treatment arm were alive compared to 24% of patients in just the Opdivo arm. In addition, this improvement was also seen in the PD-L1 negative tumor subgroup, with 38% of those patients alive at two years on the Eganelisib plus Opdivo arm versus only 17% on the Opdivo arm. These encouraging results are the key factor behind the recent rally in the stock. The only other active study is MARIO-1, which is in a far earlier stage of development, so is not germane to this analysis. Analyst Commentary & Balance Sheet: Over the past six months, five analyst firms including Piper Sandler and Oppenheimer have reissued Buy ratings on the stock. Albeit, three of these contain downward price target revisions. Price targets proffered range from $3 to $9 a share. JonesTrading maintained its Hold rating on INFI on August 12th.
Articolo di analisi • May 23

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Dec 29

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 25

Investigating Infinity Pharmaceuticals

Today we tee up a small 'off the radar' oncology concern called Infinity Pharmaceuticals for some in-depth research. The company posted encouraging trial results in July and is working with large drug makers to establish its primary candidate as part of combo therapies. A full investment analysis follows in the paragraphs below.
Articolo di analisi • Jul 18

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jun 03

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
Articolo di analisi • Apr 13

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Infinity...
Articolo di analisi • Feb 19

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

If you want to know who really controls Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ), then you'll have to look at the...
Articolo di analisi • Jan 15

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
Articolo di analisi • Dec 11

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Seth Tasker rispetto agli utili di Infinity Pharmaceuticals?
DataCompenso totaleStipendioUtili della società
Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$43m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021n/an/a

-US$45m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$1mUS$386k

-US$40m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$653kUS$368k

-US$47m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018n/an/a

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$41m

Dec 31 2017US$1mUS$320k

-US$42m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Seth sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Seth è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Seth Tasker (44 yo)

7.7yrs
Mandato
US$1,435,444
Compensazione

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Anthony Evnin
Independent Director17.5yrsUS$93.08k0.24%
$ 0.2
Norman Selby
Lead Independent Director12yrsUS$125.82k0.017%
$ 0.01
David Beier
Independent Director5.9yrsUS$85.58k0.0097%
$ 0.009
Roy Steven Herbst
Member of Scientific Advisory Board6yrsNessun datoNessun dato
David Munn
Member of Scientific Advisory Board6yrsNessun datoNessun dato
F. Hodi
Member of Scientific Advisory Board6yrsNessun datoNessun dato
Richard B. Gaynor
Independent Director4yrsUS$83.08k0%
$ 0
Dmitry Gabrilovich
Member of Scientific Advisory Board6yrsNessun datoNessun dato
Jeffery Kutok
Chairman of Scientific Advisory Board4yrsUS$759.67kNessun dato
Samuel Agresta
Chair of Clinical Advisory Boardno dataUS$73.08k0.012%
$ 0.01
Toni Choueiri
Member of Clinical Advisory Boardno dataNessun datoNessun dato
Michael Postow
Member of Clinical Advisory Boardno dataNessun datoNessun dato
6.0yrs
Durata media
71yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di INFI.Q sono considerati esperti (durata media dell'incarico 6 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/03/11 17:16
Prezzo dell'azione a fine giornata2024/03/11 00:00
Utili2023/06/30
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Infinity Pharmaceuticals, Inc. è coperta da 23 analisti. di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Christopher RaymondBaird
Andrew D'SilvaB. Riley Securities, Inc.
Michael KingCitizens JMP Securities, LLC